SGLT inhibitor adjunct therapy in type 1 diabetes

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
sitagliptin 1 endocrinologydiseasesdrugs
Insulin 1 endocrinologydiseasesdrugs
Pramlintide 1 endocrinologydiseasesdrugs
dapagliflozin 17 endocrinologydiseasesdrugs
diabetic ketoacidosis 2 endocrinologydiseases
metformin 2 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Insulin 7415 stabilised on insulin, to receive dapagliflozin (1, 2.5, 5 or 10 mg) or placebo over 2 weeks [[22]]. Insulin doses were not proactively reduced but were adjusted based on capillary blood glucose for safety. Dapagliflozin
Pramlintide 3065 adjunct therapy in type 1 diabetes were small, short-term and generally had unimpressive outcomes [[9]]. Pramlintide , currently licensed only in the USA, was one of few agents shown to be effective, but its beneficial
dapagliflozin 899 Inadequately Controlled Type 1 Diabetes (DEPICT-1) and inTandem3, have reported that SGLT inhibition with dapagliflozin and sotagliflozin, respectively, confer additional benefits in terms of a 5–6 mmol/mol (0.4–0.5%)
dapagliflozin 5232 and augments the release of gastrointestinal incretins. Selective SGLT2 inhibitors (empagliflozin, dapagliflozin , canagliflozin) or dual SGLT1/SGLT2 inhibitors (sotagliflozin) are therefore an attractive therapeutic
dapagliflozin 7346 adults with type 1 diabetes (HbA1c 53–86 mmol/mol [7–10%]), stabilised on insulin, to receive dapagliflozin (1, 2.5, 5 or 10 mg) or placebo over 2 weeks [[22]]. Insulin doses were not proactively reduced but
dapagliflozin 14869 data from DEPICT, inTandem1 and inTandem2CSII, Continuous subcutaneous insulin infusion (pump); DAPA, dapagliflozin ; DDS2, Diabetes Distress Scale 2; DTSQ, Diabetes Treatment Satisfaction Questionnaire; FPG, fasting
dapagliflozin 16907 −3.0 kg (p < 0.001)aThis table shows 24 week data from DEPICT, inTandem1 and inTandem2DAPA, dapagliflozin ; NA, data not publicly available; PBO, placebo; SH, severe hypoglycaemia; SOTA, sotagliflozinTable 3Number
dapagliflozin 18906 as n (%), these data were not availableCSII, continuous subcutaneous insulin infusion (pump); DAPA, dapagliflozin ; PBO, placebo; SH, severe hypoglycaemia; SOTA, sotagliflozinThe 24 week data from two further ongoing
dapagliflozin 19562 24 week study in 833 individuals with type 1 diabetes, in which participants were randomised to receive dapagliflozin 5 mg or 10 mg or placebo (Table 1) after a run-in period of 8 weeks to optimise glycaemic control.
dapagliflozin 20234 duration of type 1 diabetes of 20.3 (±11.8) years (Table 1) [[28]]. In this trial, the addition of dapagliflozin (5 mg or 10 mg) vs placebo to type 1 diabetes therapy resulted in a significant reduction HbA1c (mean
dapagliflozin 20501 [−0·42%] [95% CI −0·56, −0·28] and −4 mmol/mol [−0·45%] [95% CI −0·58, −0·31] for dapagliflozin 5 mg and 10 mg, respectively, both p < 0.0001 vs placebo) (Table 2). This improvement in HbA1c
dapagliflozin 20779 change at week 24 was −2.96% [95% CI −3.63, −2.28] and −3.72% [95% CI −4.38, −3.05] for dapagliflozin 5 and 10 mg, respectively, both p < 0.001 vs placebo) and total daily insulin dose (mean difference
dapagliflozin 20973 insulin dose (mean difference −8.8% [95% CI −12.6, −4.9] and −13.2% [95% CI −16.8, −9.4] for dapagliflozin 5 mg and 10 mg, respectively, p < 0.001 vs placebo). The proportional reductions seen for basal
dapagliflozin 21205 insulin doses individually were similar in percentage to the total insulin dose reduction for each of the dapagliflozin doses. CGM revealed modest but significant reductions in glucose variability with both doses of dapagliflozin.
dapagliflozin 21315 dapagliflozin doses. CGM revealed modest but significant reductions in glucose variability with both doses of dapagliflozin . For instance, the time spent in the target glucose range (>3.9 mmol/l to <10.0 mmol/l) was increased
dapagliflozin 21511 <10.0 mmol/l) was increased from 43.2 ± 12.4% to 52.3 ± 14.8% (p < 0.05) after 24 weeks of dapagliflozin 10 mg. Again, adverse events were not uncommon, with more genital infections occurring with dapagliflozin
dapagliflozin 21618 dapagliflozin 10 mg. Again, adverse events were not uncommon, with more genital infections occurring with dapagliflozin vs placebo (Table 3). Hypoglycaemia (all categories) did not occur more frequently with dapagliflozin.
dapagliflozin 21720 dapagliflozin vs placebo (Table 3). Hypoglycaemia (all categories) did not occur more frequently with dapagliflozin . DKA was infrequent in all groups (1–2%) and was not increased significantly by dapagliflozin [[28]].
dapagliflozin 21816 with dapagliflozin. DKA was infrequent in all groups (1–2%) and was not increased significantly by dapagliflozin [[28]]. However, adjudication of suspected DKA differed between the DEPICT-1 and inTandem3 trials and
metformin 3737 effectiveness of the glucagon-like peptide-1 receptor agonist liraglutide (1.2 mg and 1.8 mg doses) and metformin , respectively, as adjuncts to insulin therapy in type 1 diabetes. In ADJUNCT ONE, liraglutide showed
metformin 4300 label indication for liraglutide in type 1 diabetes. Similarly, despite the frequent off-label use of metformin in type 1 diabetes [[9], [16]], in the REMOVAL study it failed to significantly reduce carotid intima–media
sitagliptin 3311 small and the risk of hypoglycaemia was increased [[10]]. Of the dipeptidyl peptidase-4 inhibitors, sitagliptin is the most widely studied as adjunct therapy in type 1 diabetes, but no major benefit was seen in three
Select Disease Character Offset Disease Term Instance
diabetic ketoacidosis 1233 does not come with a significantly increased risk of hypoglycaemia but does carry an increased risk of diabetic ketoacidosis and mycotic infections. These results suggest that SGLT inhibition will have a place in the management
diabetic ketoacidosis 6763 monitoring (CGM) were less frequent compared with baseline. Two participants withdrew early because of diabetic ketoacidosis (DKA) (associated with severe gastroenteritis in one and pump failure in the other).In a placebo-controlled,

You must be authorized to submit a review.